| Species |
Human |
| Protein Construction |
GDF-2/BMP-9 (Ser320-Arg429)
Accession # Q9UK05 |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its ability to induce alkaline phosphatase production by ATDC5 mouse chondrogenic cells. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
12.08 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 13-15 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in 4mM HCL. |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in 4mM HCL. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Bone morphogenetic proteins (BMPs) are expressed in different cell types of the human ovarian follicle and play important roles in the regulation of ovarian function. BMP-9, also known as growth differentiation factor-2 (GDF-2), belongs to the transforming growth factor-beta (TGF-β) superfamily. BMP-9 is mainly synthesized in the liver and secreted into the blood which allows it to regulate various physiological and pathological functions. |
| Synonyms |
GDF-2; GDF2; BMP-9; BMP9 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
